1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
  4. > Global Hemophilia B Market 2015-2019 - Industry Analysis

Global Hemophilia B Market 2015-2019 - Industry Analysis

  • September 2015
  • -
  • Infiniti Research Limited
  • -
  • 60 pages

About hemophilia B
Hemophilia B, also called the Christmas disease, is a blood coagulation disorder due to the deficiency or improper function of factor IX. It is inherited in an X-linked recessive pattern. This disorder is more prevalent in males than in females. Factor replacement therapies, mainly recombinant, are used in the treatment.

Technavio's analysts forecast the global hemophilia B market to grow posting a CAGR of 4.18% over the period 2014-2019.

Covered in this report
The report includes the present scenario and the growth prospects of the global hemophilia B market for 2015-2019. To calculate the market size, the report considers revenue generated from the sales of various drugs used in the treatment of hemophilia B.

Technavio's report, Global Hemophilia B Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the market size and forecast as well as market segmentation and landscape. The report includes a discussion of the key vendors operating in this market.

Key regions
- Americas
- APAC
- EMEA

Key Vendors
- Baxter
- Grifols
- Novo Nordisk
- Pfizer

Other prominent vendors
- Alnylam
- Amarna
- Asklepios
- Biogen
- Catalyst Biosciences
- CSL Behring
- Dimension Therapeutics
- Dong-A Scio
- Emergent BioSolutions

Key market driver
- Prophylactic treatment
- For a full, detailed list, view our report

Key market challenge
- High cost of therapy
- For a full, detailed list, view our report

Key market trend
- New technological advancements
- For a full, detailed list, view our report


Key Questions Answered in this Report
- What will the market size be in 2019 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?

Table Of Contents

Global Hemophilia B Market 2015-2019 - Industry Analysis
PART 01: Executive summary
Highlights
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 06: Disease overview
Understanding the disease
Epidemiology
PART 07: Pipeline portfolio
Key information of few pipeline candidates
PART 08: Market segmentation by disease severity
Mild hemophilia B
Moderate hemophilia B
Severe hemophilia B
PART 09: Market segmentation by disease management
On-demand therapy
Prophylactic therapy
Inhibitor therapy
PART 10: Geographical segmentation
PART 11: Market drivers
Focus on prophylactic treatment
Drugs with prolonged action
Patient assistance programs
PART 12: Impact of drivers
PART 13: Market challenges
High cost of therapy
Low diagnosis rate in developing countries
Complications of available therapies
PART 14: Impact of drivers and challenges
PART 15: Market trends
Advances in technology
Strategic alliances
Development of gene therapy products
PART 16: Vendor landscape
Competitive scenario
Mergers and acquisitions
Market share analysis 2014
Other prominent vendors
PART 17: Key vendor analysis
Baxter
Grifols
Novo Nordisk
Pfizer
PART 18: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global hemophilia B market 2014-2019 ($ billions)
Exhibit 03: Five forces analysis
Exhibit 04: Global cases of hemophilia B 2010-2013
Exhibit 05: Cases of Hemophilia B by region 2012
Exhibit 06: Cases of hemophilia B by region 2013
Exhibit 07: Global hemophilia B market segmentation by disease severity
Exhibit 08: Global hemophilia B market segmentation by disease severity 2014
Exhibit 09: Treatment of severe hemophilia B 2014
Exhibit 10: Global hemophilia B market segmentation by disease management
Exhibit 11: Share of prophylactic therapy by region 2014
Exhibit 12: Types of prophylaxis
Exhibit 13: Global hemophilia B market segmentation by disease management 2014
Exhibit 14: Global hemophilia B market segmentation 2014
Exhibit 15: Global hemophilia B market segmentation by revenue 2014 ($ billions)
Exhibit 16: Impact of drivers
Exhibit 17: Impact of drivers and challenges
Exhibit 18: Baxter: Global sales of hemophilia B drugs 2014-2017 ($ millions)
Exhibit 19: Baxter: Key takeaways
Exhibit 20: Grifols: Key takeaways
Exhibit 21: Novo Nordisk: Global sales of NovoSeven 2011-2014 ($ millions)
Exhibit 22: Novo Nordisk: Key takeaways
Exhibit 23: Pfizer: Global sales of BeneFIX 2011-2014 ($ millions)
Exhibit 24: Pfizer: Key takeaways
Exhibit 25: Novo Nordisk: Business segmentation by revenue 2014
Exhibit 26: Novo Nordisk: Business segmentation by revenue 2013 and 2014
Exhibit 27: Novo Nordisk: Geographical segmentation by revenue 2014
Exhibit 28: Novo Nordisk: RandD expenditure 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Drugs and Diagnostics for Hematological Disorders: Global Markets

Drugs and Diagnostics for Hematological Disorders: Global Markets

  • $ 6650
  • Industry report
  • September 2016
  • by BCC Research

Use this report to: - Receive detailed information regarding screening, testing and treatment options for hematological disorders and blood cancer. - Learn about the types of diagnostic and treatment ...

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

Sepsis Diagnostics Market by Technology, Product, Method, Usability, Pathogen - Global Forecast to 2021

  • $ 5650
  • Industry report
  • September 2016
  • by MarketsandMarkets

The sepsis diagnostics market is expected to reach USD 564.1 million by 2021, at a CAGR of 8.8% from 2016 to 2021. The sepsis diagnostics market is primarily driven by the rising prevalence of sepsis in ...

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy

  • $ 4995
  • Industry report
  • November 2016
  • by GBI Research

Hemophilia A and B Therapeutics in Asia-Pacific Markets to 2022 - Growth Driven by Increasing Treatment-Receiving Pool, Launch of Long-Acting Replacement Therapies and Non-factor Therapy Summary Hemophilia ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.